The uncomfortable math behind British Columbia’s life sciences boom is simple: the province produces world-class science and trains elite researchers, only to watch the resulting intellectual property commercialized elsewhere.

Metro Vancouver’s research institutions—including UBC, SFU, and the BC Cancer Agency—generate drug discovery output that punches well above Canada’s weight. The sector generated an estimated $17 billion in total economic impact in 2024, according to Life Sciences BC. However, economic impact and IP ownership are distinct metrics. A growing share of the molecular assets, platform technologies, and therapeutic candidates emerging from these institutions are licensed to American commercialization partners before they reach a Canadian clinical or regulatory pathway.

This is not a failure of founder decision-making. It is a result of structural incentives that make the American path appear rational—and that rationality carries a high cost for BC over the long term.

The Three Fault Lines

Talk to founders in Vancouver’s life sciences corridor and three pressure points surface repeatedly.

The first is capital. Series B financing for drug development in Canada remains thin. The venture funds capable of writing $30-million-to-$80-million cheques into pre-revenue biotech—the capital required to own an IND filing and Phase I trial—are largely American. Canadian institutional investors have historically underweighted life sciences relative to their US counterparts, and the domestic Series B market has not kept pace with the volume of spinouts emerging from BC research institutions.

The Business Development Bank of Canada has expanded its life sciences lending programs, and federal granting bodies like CIHR and NSERC continue to fund early-stage research. However, a recognized "valley of death" exists between CIHR-funded discovery science and the capital required to own a drug through Phase II. That valley is where licensing deals are signed.

The second fault line is regulatory timing. Health Canada's drug review timelines have historically run longer than the FDA's. For a startup burning cash while awaiting regulatory clarity, time is a significant cost. The FDA’s Breakthrough Therapy and Fast Track designations offer accelerated pathways that lack direct Canadian equivalents at the same scale. For a founder choosing between a Canadian or American regulatory strategy, the FDA’s infrastructure—and its predictability—provides a competitive advantage for US partners.

The third fault line is grant architecture. While some NIH basic research grants are open to foreign applicants, NIH commercialization grants—specifically SBIR and STTR programs—are strictly barred to Canadian-majority-owned companies. When a licensing deal transfers commercialization rights to a US entity, the new owner gains access to funding streams that were structurally unavailable to the Canadian originator.

What the Deals Look Like

A common pattern has emerged in Vancouver's drug discovery ecosystem. A UBC or BC Cancer Agency spinout often retains a royalty stream—typically in the low-to-mid single digits—while transferring exclusive global commercialization rights to a US-based partner. While the Canadian entity may retain a right of first negotiation for Canadian commercialization, that right is rarely exercised at scale.

UBC's University-Industry Liaison Office is one of the most active technology transfer offices in Canada, consistently ranking among the top institutions for spinout formation. Yet, the number of UBC-originated companies that retain Canadian majority ownership through clinical-stage development remains a small subset of total activity.

The royalty model validates the science, but it trades compounding equity value for a fixed income stream. The company that owns the drug through approval captures the asymmetric upside; the royalty holder captures only a fraction.

The Capital Gap in Practice

Genome BC has supported dozens of companies through its commercialization programs, providing meaningful early-stage support. The gap appears at the transition from proof-of-concept to clinical development, where capital requirements increase by an order of magnitude.

BC’s SR&ED tax credit program provides relief on R&D expenditures, and BC life sciences SMEs are active users of the federal SR&ED credit. However, SR&ED is a cost offset, not growth capital. Following the 2021 launch of the federal Biomanufacturing and Life Sciences Strategy, the government committed significant funding in 2023 to bolster the sector. Whether these commitments translate into the patient, risk-tolerant Series B capital required to keep IP in Canadian hands remains the central question.

The Emerging Domestic Alternatives

The structural problem is evolving. A small cohort of Canadian institutional investors—including pension-adjacent vehicles and family offices—has begun building life sciences exposure with longer time horizons. While they are not yet writing the $50-million cheques that define US Series B rounds, the shift is notable.

Life Sciences BC has actively advocated for regulatory reform, pushing for Health Canada pathway improvements to narrow the timeline gap with the FDA. Concurrently, the BC Tech Association's life sciences sub-sector has prioritized IP retention as a key component of the province's innovation economy.

Ultimately, founders are increasingly treating IP ownership as a strategic asset from day one. While royalty streams provide necessary revenue, equity in a drug that reaches the market represents a different class of value. The province’s research output remains world-class; the challenge lies in building the infrastructure to capture the compounding value of that science.